Drugs of the Future

Papers
(The median citation count of Drugs of the Future is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 20223
Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease3
Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor, Treatment of multiple sclerosis2
Navtemadlin. MDM2-p53 interaction inhibitor, Treatment of cancer1
Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection1
Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity1
Mobocertinib. EGFR ex20ins-specific tyrosine kinase inhibitor, Treatment for non-small cell lung cancer1
American Association for Cancer Research (AACR) - 113th Annual Meeting. New Orleans/Virtual - April 8-13, 20221
Pelacarsen. Antisense oligonucleotide targeting apolipoprotein(a), Treatment of lipoprotein disorders, Treatment of cardiovascular diseases1
American Society of Clinical Oncology (ASCO) – 58th Annual Meeting. Chicago/Virtual – June 3-7, 20221
Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2− and HER2+ advanced breast cancer1
Navafenterol. Dual M3 receptor antagonist/β2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease1
Zimberelimab. Anti-programmed cell death protein 1 (PD-1) monoclonal antibody, Treatment of Hodgkin lymphoma, Treatment of advanced solid tumors1
Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer1
Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases1
Donanemab. Monoclonal antibody targeting N3pG β-amyloid, Treatment of early Alzheimer's disease1
Pipeline on the Move0
Entospletinib. Spleen tyrosine kinase (SYK) inhibitor, Hematological cancer therapy0
Society for Immunotherapy of Cancer (SITC) – 37th Annual Meeting. Boston/Virtual – November 8-12, 20220
European Federation of Medicinal Chemistry - XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022). Nice - September 4-8, 20220
Society for Neuroscience - 50th Annual Meeting. Virtual - November 8-11, 20210
Association for Research in Vision and Ophthalmology (ARVO) - 2022 Annual Meeting. Denver/Virtual - May 1-4 and 11-12, 20220
Association for Cancer Immunotherapy (CIMT) - 19th Annual Meeting. Mainz/Virtual - May 10-12, 20220
NME Digest0
Recent Clinical Disclosures and SMR Award. Highlights from the Society for Medicines Research Conference. Virtual - December 2, 20210
Pipeline on the Move0
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma0
Relacorilant. Glucocorticoid receptor antagonist, Treatment of Cushing syndrome, Treatment of prostate cancer, Treatment of ovarian cancer0
Uproleselan sodium. E-selectin antagonist, Treatment of acute myeloid leukemia0
Pipeline on the Move0
Avacincaptad pegol. Complement C5 inhibitor, Treatment of geographic atrophy secondary to dry age-related macular degeneration, Treatment of Stargardt d0
Sabatolimab. TIM-3-targeting monoclonal antibody, Treatment of myelodysplastic syndrome, Treatment of acute myeloid leukemia0
Pipeline on the Move0
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity0
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 20220
Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-190
Therapeutic targets for giant cell arteritis0
Ancremonam. Monobactam, Treatment of multidrug-resistant Enterobacteriaceae infections0
Glofitamab. Anti-CD20 T-cell–engaging bispecific antibody, Treatment of non-Hodgkin lymphoma0
Erfonrilimab. Bispecific anti-PD-L1/CTLA-4 antibody, Cancer immunotherapy0
NME Digest0
Society for the Study of Inborn Errors of Metabolism – 2022 Annual Symposium. Freiburg – August 30-September 2, 20220
Pipeline on the Move0
American Society for Clinical Pharmacology and Therapeutics – 123rd Annual Meeting. Virtual – March 16-18, 20220
AACR-NCI-EORTC - 34th International Symposium on Molecular Targets and Cancer Therapeutics. Barcelona - October 26-28, 20220
NME Digest0
AACR-NCI-EORTC - 33rd International Symposium on Molecular Targets and Cancer Therapeutics. Virtual - October 7-10, 20210
American Society of Hematology - 63rd Annual Meeting and Exposition. Virtual/Atlanta - December 11-14, 20210
Zandelisib. Phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, Treatment of B-cell lymphomas0
IDWeek 2022. Washington, D.C. - October 19-23, 20220
American Chemical Society (ACS) – 264th National Meeting and Exposition. Chicago/Virtual – August 21-25, 20220
Tavokinogene telsaplasmid. DNA-based interleukin-12 (IL-12), Gene therapy, Treatment of metastatic melanoma, Treatment of triple-negative breast cancer,0
American Society of Tropical Medicine and Hygiene, 70th Annual Meeting. Virtual - November 17-21, 20210
21st RSC/SCI Medicinal Chemistry Symposium. Cambridge/Virtual - September 13-15, 20210
Society for Immunotherapy of Cancer (SITC) - 36th Annual Meeting. Virtual - November 10-14, 20210
American Association for the Study of Liver Disease (AASLD) - The Liver Meeting. Virtual - November 12-15, 20210
Crovalimab. Anti-C5 monoclonal antibody, Treatment of paroxysmal nocturnal hemoglobinuria, Treatment of atypical hemolytic uremic syndrome, Treatment of0
Tebipenem pivoxil hydrobromide. Penicillin-binding protein (PBP) (bacterial) inhibitor, Carbapenem antibiotic, Treatment of urinary tract infections0
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases0
Experimental and in silico approaches to target selection and tractability for drug discovery. Highlights from the Society for Medicines Research Confer0
NME Digest0
Tanfanercept. Recombinant variant of human TNFR1, TNF-α modulator, Treatment of dry eye disease0
Lenadogene nolparvovec. rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy0
Alzheimer's Association International Conference (AAIC) 2022. San Diego – July 31-August 4, 20220
Nirsevimab. Anti-glycoprotein F (respiratory syncytial virus) monoclonal antibody, Prevention of respiratory syncytial virus-associated illness0
United European Gastroenterology Week (UEGW) 2021 - 29th Annual Conference. Virtual - October 3-5, 20210
American Heart Association (AHA) Scientific Sessions - 2021 Annual Meeting. Virtual - November 13-15, 20210
Advances in Genetic Medicine. Highlights from The Society for Medicines Research Online Meeting. Virtual -December 3, 20200
American Society of Gene and Cell Therapy (ASGCT) – 25th Annual Meeting. Washington, D.C./Virtual - May 16-19, 20220
Taletrectinib adipate. Dual ROS1 and NTRK inhibitor, Treatment of non-small cell lung cancer, Treatment of solid tumors0
Pipeline on the Move0
American Heart Association (AHA) Scientific Sessions - 2022 Annual Meeting. Chicago/Virtual - November 5-7, 20220
Pipeline on the Move0
Nafithromycin. Ketolide antibiotic, Treatment of community-acquired bacterial pneumonia0
The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 20220
NCX-470. Nitric oxide-donating prostaglandin analogue, Treatment of glaucoma, Treatment of ocular hypertension0
Pruxelutamide. Androgen receptor antagonist, Treatment of metastatic castration-resistant prostate cancer, Treatment of metastatic breast cancer0
Lisavanbulin. Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme0
32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Lisbon/Virtual - April 23-26, 20220
Cefepime/taniborbactam. Fixed-dose combination, Cephalosporin beta-lactam antibiotic/beta-lactamase inhibitor, Treatment of complicated urinary tract in0
Innovative new pharma and biotech partnerships: How is the landscape transforming? Highlights from the Society for Medicines Research Conference. Steven0
Rationale of ferroportin inhibition for beta-thalassemia management0
Pipeline on the Move0
American Society for Microbiology (ASM) Microbe – 2022 Annual Meeting. Washington, D.C. – June 9-13, 20220
Adagrasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer0
American Society of Human Genetics Annual Meeting. Virtual - October 18-22, 20210
Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors0
Targets to watch in neuroinflammation: focus on RIPK10
Therapeutic targets for dermatomyositis0
Cefepime/enmetazobactam. β-Lactam/β-lactamase inhibitor, Treatment of complicated urinary tract infection0
NME Digest0
Therapeutic targets for paroxysmal nocturnal hemoglobinuria0
Pipeline on the Move0
European Society of Gene and Cell Therapy (ESGCT) - 28th Annual Meeting. Virtual - October 19-22, 20210
European Society of Medical Oncology (ESMO) - 2021 Annual Congress. Virtual - September 16-21, 20210
European Respiratory Society - 32nd International Congress. Barcelona - September 4-6, 20220
Pipeline on the Move0
American Society of Nephrology's (ASN) Kidney Week - 2022 Annual Meeting. Orlando - November 3-6, 20220
Pipeline on the Move0
American Chemical Society – 263rd National Meeting and Exposition. Virtual/San Diego – March 20-24, 20220
Sonelokimab. Interleukin-17A and -F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa0
San Antonio Breast Cancer Symposium 2021 - 44th Annual Meeting. Virtual/San Antonio - December 7-10, 20210
Pipeline on the Move0
Kidney Week 2021. Virtual - November 4-7, 20210
Bomedemstat tosylate. Lysine-specific demethylase 1 inhibitor, Treatment of essential thrombocythemia, Treatment of polycythemia vera, Treatment of myel0
American Academy of Neurology (AAN) - 74th Annual Meeting: The Great Neuro Reunion. Seattle - April 2-7, 20220
The 40th Annual J.P. Morgan Healthcare Conference. Virtual - January 10-13, 20220
Tinlarebant. Retinol-binding protein 4 (RBP4) inhibitor, Treatment of Stargardt disease, Treatment of dry age-related macular degeneration0
Pipeline on the Move - May 20220
Xeruborbactam. Ultrabroad-spectrum β-lactamase inhibitor, Treatment of bacterial infections0
European Association of Nuclear Medicine – 35th Annual Congress. Barcelona – October 15-19, 20220
RGX-314. AAV8 gene therapy encoding anti-VEGF Fab, Treatment of wet age-related macular degeneration, Treatment of diabetic retinopathy0
European Society of Medical Oncology (ESMO) - 2022 Annual Congress. Paris/Virtual - September 9-13, 20220
Pipeline on the Move0
Biomarkers in frontotemporal dementia: a narrative review0
International Association for the Study of Lung Cancer (IASLC) – 23rd World Conference on Lung Cancer (WCLC 2022). Vienna – August 6-9, 20220
An overview of prophylaxis and treatment indications for COVID-19-related thrombotic complications0
Ciltacabtagene autoleucel. CAR-T therapy targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma0
European Association for Cancer Research (EACR) – 28th Annual Meeting. Seville – June 20-23, 20220
Paxalisib. PI3K/mTOR inhibitor, Treatment of gliomas0
BIO-Europe Spring Digital 2022 – 16th Annual Partnering Conference. Virtual – March 28-31, 20220
Pipeline on the Move0
Efanesoctocog alfa. Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein, Treatment of hemophilia A0
European Association for the Study of Diabetes (EASD) – 58th Annual Meeting. Stockholm/Virtual – September 19-23, 20220
Positioning of hafnium oxide nanoparticles therapy in cancer treatment0
Gene therapy in the fight against pediatric blood disorders: sickle cell disease and β-thalassemia0
Gene therapies for achromatopsia under clinical evaluation0
0.024426937103271